Health Economics›Melanoma›Advanced or metastatic disease BRAF inhibitor-naive

Advanced or metastatic disease BRAF inhibitor-naive

Melanoma · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 9 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cobimetinib, Vemurafenib, Atezolizumab Variant #01	BRAF	R 117 201	28d	15.1 mo	—	17	R 1 992 417 PFS proxy	1
Ipilimumab and Nivolumab Variant #01 Partial	BRAF	R 78 615	42d	~11.5 mo	~72.0 mo	~9	~R 707 538 PFS proxy · indirect	6
Cobimetinib and Vemurafenib Variant #01	BRAF	R 54 932	28d	11.5 mo	22.3 mo	13	R 714 112 PFS proxy	3
Dabrafenib and Trametinib Variant #01	BRAF	R 52 791	28d	10.7 mo	—	12	R 633 492 PFS proxy	5
Trametinib monotherapy Variant #01	BRAF	R 26 396	28d	4.9 mo	—	6	R 158 373 PFS proxy	2
Dabrafenib monotherapy Variant #01	BRAF	R 26 396	28d	5.5 mo	—	6	R 158 373 PFS proxy	4
Vemurafenib monotherapy Variant #01	BRAF	R 13 464	28d	7.2 mo	15.5 mo	8	R 107 711 PFS proxy	4
Paclitaxel monotherapy Variant #46	BRAF	R 2 220	28d	1.7 mo	9.4 mo	2	R 4 439 PFS proxy	4
Dacarbazine monotherapy Variant #01	BRAF	R 2 094	21d	1.5 mo	9.6 mo	3	R 6 282 PFS proxy	6
Binimetinib and Encorafenib Variant #01 Partial	BRAF	—	28d	14.9 mo	33.6 mo	17	—	2

10 of 10 regimens shown